Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ).
Journal of Psychosomatic Research. 2025-08-01; 195: 112192
DOI: 10.1016/j.jpsychores.2025.112192
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/11662
Tokarski R(1), Barbosa S(2), Pignon B(3), Aouizerate B(4), Andrieu C(5), Andre
M(6), Boukouaci W(3), Capdevielle D(6), Chereau I(7), Dondé C(8), Kobayashi
JC(9), Dorey JM(10), Dubertret C(11), Fakra E(12), Fond G(5), Goze T(13),
Leignier S(14), Llorca PM(7), Mallet J(11), Misdrahi D(15), Oriol N(12), Rey
R(10), Roux P(16), Schürhoff F(3), Schorr B(9), Szöke A(3), Urbach M(16), Very
E(13), Wu CL(3); FACE-SZ group; Leboyer M(3), Tamouza R(3), Godin O(17).
Author information:
(1)Université Paris Est Créteil (UPEC), INSERM, Institut Henri Mondor the
Recherche Biomédicale, Laboratoire Neuro-Psychiatrie Translationnelle, Créteil,
France.
(2)Université Côte d’Azur, Centre National de la Recherche Scientifique,
Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
(3)Fondation FondaMental, Créteil, France; Université Paris Est Créteil (UPEC),
INSERM, Institut Henri Mondor the Recherche Biomédicale, Laboratoire
Neuro-Psychiatrie Translationnelle, Créteil, France; Assistance Publique
Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Département
Médico-Universitaire de Psychiatrie et d’Addictologie, Val-de-Marne, France.
(4)Fondation FondaMental, Créteil, France; University Department of General
Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux, France; Laboratory of
Nutrition and Integrative Neurobiology (UMR INRAE 1286), University of Bordeaux,
Bordeaux, France.
(5)Fondation FondaMental, Créteil, France; AP-HM, Service Universitaire de
psychiatrie et d’addictologie (Pr Lançon), Hôpital Sainte Marguerite, 13009
Marseille, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm, 1061 Montpellier, France.
(7)Fondation FondaMental, Créteil, France; University of Clermont Auvergne,
CMP-B CHU, CNRS, Clermont Auvergne INP, Institut Pascal, F-63000
Clermont-Ferrand, France.
(8)Fondation FondaMental, Créteil, France; Univ. Grenoble Alpes, F-38000
Grenoble, France; Inserm U1216, F-38000 Grenoble, France; Psychiatry Department,
CH Alpes Isere, F-38000 Grenoble, France; Psychiatry Department, CHU Grenoble,
F-38000 Grenoble, France.
(9)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1329, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(10)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre
de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678
Bron Cedex, France.
(11)Fondation FondaMental, Créteil, France; AP-HP, Groupe
Hospitalo-universitaire AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et
Addictologie, Hôpital Louis Mourier, Colombes, France; Université de Paris
Inserm UMR1266, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
(12)Fondation FondaMental, Créteil, France; Department of Psychiatry, University
Hospital of Saint-Etienne, Saint-Etienne, France.
(13)Fondation FondaMental, Créteil, France; Department of Psychiatry,
Psychotherapies, Art-therapy, Toulouse University Hospital; Equipe de Recherche
sur les Rationalités Philosophiques et les Savoirs – EA3051, Université de
Toulouse – Jean Jaurès, Toulouse, France.
(14)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale et de Remédiation Cognitive (C3R), CH Alpes Isère, Grenoble,
France.
(15)Fondation FondaMental, Créteil, France; University of Bordeaux, Aquitaine
Institute for Cognitive and Integrative Neuroscience (CNRS UMR 5287-INCIA),
Bordeaux, France; Department of Adult Psychiatry, Charles Perrens Hospital,
Bordeaux, France.
(16)Fondation FondaMental, Créteil, France; Versailles Hospital, Department of
Adult Psychiatry and Addictology, Centre Hospitalier de Versailles, 177 rue de
Versailles, 78157 Le Chesnay, France; MOODS Team, INSERM UMR1018, CESP, Faculté
de Médecine Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines,
Université Paris-Saclay, Villejuif, France.
(17)Fondation FondaMental, Créteil, France; Université Paris Est Créteil (UPEC),
INSERM, Institut Henri Mondor the Recherche Biomédicale, Laboratoire
Neuro-Psychiatrie Translationnelle, Créteil, France. Electronic address:
.
AIMS: Recent studies on Metabolic dysfunction-associated fatty liver (MAFLD) in
schizophrenia show inconsistent findings, often based on small or specific
samples. This study aims to assess the prevalence of MAFLD and its
sociodemographic, clinical, and treatment-related risk factors in a large cohort
of chronic patients with schizophrenia. A secondary goal is to identify an
immuno-inflammatory signature associated with MAFLD.
METHODS: 1009 stable outpatients with schizophrenia were included in the
cross-sectional analysis. Individuals with liver disease, hepatitis B/C, or
current alcohol use disorder were excluded. MAFLD was screened using the Fatty
Liver Index (FLI), with FLI > 60 indicating MAFLD. Risk factors were assessed
using multivariate logistic regression, and inflammatory markers were analysed
with penalized logistic regression.
RESULTS: In a sample of 1009 individuals with schizophrenia, MAFLD prevalence
was 36.6 %, higher in men than in women (38.3 % vs 32.0 %, p